Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
personally I did a bit better today. Market's due for a correction anyway.
ok. I haven't posted on this board in a few years but that's some funny stuff there.
back to lurking
Chey, I don't know. Unfortunately on my way out the door and won't be able to research right now.
Here's some info about JYTDOG
https://en.wikipedia.org/wiki/User:Jytdog
https://disqus.com/by/jytdog/
There is a group within Wikipedia called WikiProject Medicine of which I am a part. We work our butts off, to keep woo out of Wikipedia. Our page in Wikipedia is https://en.wikipedia.org/wiki/... and the standards used in Wikipedia for sourcing content about health (which we help maintain with the support of the broader Wikipedia community), is here: https://en.wikipedia.org/wiki/...\
Jimmy Wales, the founder of Wikipedia, has been clear in his support for our work, with his response to a petition from purveyors of woo with reference to "lunatics and charlatans" (per http://arstechnica.com/science... Funny that didn't get a mention!
I for one appreciate the support, Dr. Novella. It is a constant battle and we cannot keep up every where. We are doing our best though.
Wonder if Igor Tulchinsky's in on this too.....
I'll take that bet for .96 (yeah, I know it's .98 now)
CP,
Vendor could be almost anyone. I'm in IT (in pharma). So, for me, vendor could be an owner of the lab equipment we may lease from. Could be for software maintenance, equipment calibration, troubleshooting, etc. But, they do need to be escorted. Especially in a GMP facility.
Maybe we should just call you Happy
I like the sound of that North!
Best to all
B
Bio,
PI - https://clinicaltrials.gov/ct2/show/NCT01264705?term=bavituximab&rank=10
This phase I, open-label single institution trial of bavituximab plus sorafenib was conducted between March and October 2011. The study was designed with a traditional 3 + 3 dose escalation rule with a fixed dose of sorafenib (400 mg PO BID) and escalating dosages of bavituximab. Based on previous clinical trials, the bavituximab dosage was escalated from 0.3 to 1.0 to 3 mg/kg intravenously weekly.19 Following one cycle of treatment, continuation of sorafenib was at the discretion of the treating physician.
Dose-limiting toxicities (DLTs) were captured over the first 28 days of treatment (first cycle) and were predefined including: grade 4 neutropenia and thrombocytopenia ≥7 days (absolute granulocyte count <0.5 × 109/l), platelet count <25,000, ALT or AST levels ≥grade 3 adverse event for 7 days, and ≥grade 3 adverse event for any nonhematologic toxicity. CTCAE version 4.0 was used for grading of all adverse events related to treatment.
So, there will still be data to be gleaned from the PII phase....
Please note there was a difference in the status of patient functionality in these trials as well.
PII - (ECOG) Performance Status ≤ 2
PIII - (ECOG) performance status of 0 or 1
Just random conjecture.
Someone in the know discovers on Friday, Jan 29th, that the PIII trial has completed enrollment and figures hey, let some people know and hopefully buy before a PR is released. 4pm EST arrives and no PR, people sell, others see others selling and it cascades driving the price down. But, other people in the know keep buying up the dropping shares because, Hey, they know!
Since it's up to the Investigator to update clinicaltrials.gov they don't get around to it until Monday, the 1st. But still, no PR. clinicaltrials.gov doesn't actually process the request until yesterday and that's why it shows today as being processed last night.
Again, EOD and people buy in figuring there may be a PR tonight. We close green. But, no PR.
again, just random thoughts......
Buffet does not invest in Biotech AT ALL.
Berkshire does have holdings in JNJ, GSK, & SNY.
However, he has admitted to not following pipelines of these companies.
Fantastic!
All future objections should include the same :)
http://www.kccllc.net/gtat/document/1411916160112000000000003
do the sharks have lasers? If so, go for it.
I wouldn't put much faith in Starmine (what Fidelity uses). Look at the accuracy rates of some of these firms. Naturally, Zachs, gets the time correct twice a day, LOL. I don't know much about Thomson Reuters investments anymore, used to work for their investment services back in 2000 (for a short time).
EDIT: Go figure, StarMine is powered by Thomson.....
There appears to be another Biotech Investor conference in San Francisco during the same time. I guess they try to piggyback off of JP Morgan:
http://www.ebdgroup.com/bts/index.php
Not implying anything but it's just worth noting.
Great to see a bit of diversity there. Now, add in 3-4 new clients and production and backlog increase more :)
TBD within the next year, will we meet on Beer Street or Gin Lane?
Sounds good to me. However, Wook may get sidetracked upgrading his fur in Flemington.....
Joisey Jam? Lemme guess, Cherry Hill? LOL.
No worries, maybe a shore town? I have my place in Philly and it's not too far a ride from RI :)
2 of the top 10 readings every week:
PPHM
IGGLES
FLY!!!!
For a second there I read CARTMAN.
Whew, keep south park out of this.
My personal opinion, I'm happy with the numbers presented here.
AVID revenue, possibility of $75 million for 2016?
Wistar site shows 5:30pm (EST)
http://www.wistar.org/EIS2015
Edit: what's interesting is that Dmitri's name is not mentioned on the Wistar events page.
MD, have you ever had any contact with this woman? - http://www.healthwriterhub.com/meet-marijke-vroomen-durning-rn-medical-writer/
Might be worth picking her brain?
http://www.targetedonc.com/publications/special-reports/2015/nsclc-issue9/immunotherapy-becoming-mainstay-of-nsclc-therapy
Correct Bio,
Abstracts are due by February 2nd. This is a P1 and unfortunately not eligible for late breaking (only PII & PIII). But, since this is open label they should have enough information for a submission.
12 week treatment plan. That does put it well within the trial completion date of March, 2016.
Nice.
over the past 3=4 weeks, volume appears to be increasing with price. It's not linear but it is trending up with sp.
YES!
Closing in on the 200 day ma. Adios 50 day!
Shortly? On the horizon? Fast approaching?
Nice find!
The results note that "The effect (40% to 80% reduction in CNV lesion area) was the same as that seen using an equal dose of an anti-VEGF antibody.", so could a combination of the two be synergistic and provide better results than either individually? I'm assuming this is what they were hinting at in the purpose (see below):
PURPOSE: Choroidal neovascularization (CNV) accounts for 90% of cases of severe vision loss in patients with advanced age-related macular degeneration. Identifying new therapeutic targets for CNV may lead to novel combination therapies to improve outcomes and reduce treatment burden. Our goal was to test whether phosphatidylserine (PS) becomes exposed in the outer membrane of choroidal neovascular endothelium, and whether this could provide a new therapeutic target for CNV.
Gotta love the indication reach of this molecule...
That's exactly correct! However, there are probably many of us that share that opinion; sadly, never to be proven as fact :(
APPL probably has already gained something for future use, i.e. - Hyperion and related IP. wink wink nod nod....
Why is Apple agreeing to this deal? They are wiping out the debt whether furnaces sell or not and scrapping what's left. There has to be an underlying reason for Apple to "help" GT get out of this. Thoughts?
Wook,
ESPP is usually done on a percentage withdrawal each pay period. I'm heading out the door now but if you look at number of shares they purchased over the 6 month period you can go back against their reported salary and get a good idea of what percentage they withheld for the purchases.
Cheers,
B
Shire to buy DYAX for $5.9b.
http://www.nytimes.com/2015/11/03/business/dealbook/shire-dyax-corp-deal.html
Dyax has 146 million outstanding shares and is just now starting a PIII trial for an orphan drug.
What idea does that give you for future valuation of PPHM and Bavi?
Here is PPHM:
http://www.nasdaq.com/symbol/pphm/institutional-holdings
AZN:
http://www.nasdaq.com/symbol/azn/institutional-holdings
Rennaissance Technologies is a recent int holder in PPHM.
If it can lead to immediate funding for the start of 2 PII trials, it's possible we get 3 nice PRs in December, the other being completed enrollment in Sunrise.
not bad, $20mil added to cash on hand, that's good for a wee little bit.
18,518,518 Shares of Common Stock
This prospectus supplement relates to our offer and sale of 18,518,518 shares of our common stock to one institutional investor, Eastern Capital Limited, at a negotiated price of $1.08 per share, for aggregate gross proceeds to us of approximately $20,000,000 pursuant to the terms of a Common Stock Purchase Agreement dated October 30, 2015. We did not use a sales agent or pay any commissions in connection with this offering.
Our common stock is listed on The NASDAQ Capital Market, or the NASDAQ, and trades under the symbol “PPHM”. On October 29, 2015, the last reported sale price of our common stock on the NASDAQ was $1.11 per share.
My thought is the best we can hope for is there is mention of one/couple of biotech's (without being named) actually leading this research. Since it's not a sponsored event I don't see a company name being mentioned. just my opinion.
CP, I had posted info on a couple of their new sites previously:
239357